135 results on '"Hamid, Nadira"'
Search Results
102. Abstract 18221: Flow Characteristics of CoreValve Transcatheter Aortic Valve: Implications for Calculation of Stroke Volume and Effective Orifice Area
- Author
-
Hamid, Nadira, primary, Khalique, Omar, additional, Williams, Mathew, additional, George, Isaac, additional, Nazif, Tamim M, additional, Vahl, Torsten, additional, White, Jonathan, additional, Parikh, Puja, additional, Kodali, Susheel, additional, Leon, Martin, additional, and Hahn, Rebecca, additional
- Published
- 2015
- Full Text
- View/download PDF
103. Abstract 13456: Screening for Transthyretin Cardiac Amyloidosis Using 99mTc-Pyrophosphate Scintigraphy in Patients Undergoing Transcatheter Aortic Valve Replacement
- Author
-
Narotsky, David L, primary, Kodali, Susheel K, additional, Mauer, Mathew S, additional, Bokhari, Sabahat, additional, Hamid, Nadira, additional, Pozniakoff, Ted, additional, Weinberg, Richard, additional, Nazif, Tamim M, additional, George, Isaac, additional, Vahl, Torsten, additional, Hahn, Rebecca T, additional, and Castano, Adam, additional
- Published
- 2015
- Full Text
- View/download PDF
104. TCT-327 Calcium Volume Score on Contrast-Enhanced Computed Tomography Prior to Transcatheter Aortic Valve Replacement: what’s the most accurate threshold cutoff?
- Author
-
Bettinger, Nicolas, primary, Hamid, Nadira, additional, Kodali, Susheel, additional, Hahn, Rebecca, additional, George, Isaac, additional, White, Jonathon M., additional, Parikh, Puja B., additional, Pulerwitz, Todd, additional, Leon, Martin, additional, and Khalique, Omar K., additional
- Published
- 2015
- Full Text
- View/download PDF
105. TCT-663 Anatomic and Procedural Predictors of Paravalvular Leak following Transcatheter Aortic Valve Replacement with a Self-expanding Prosthesis at a High Volume Center Including a Novel Variable of Inflow Expansion
- Author
-
Bettinger, Nicolas, primary, Hamid, Nadira, additional, Hahn, Rebecca, additional, Kodali, Susheel, additional, Vahl, Torsten P., additional, White, Jonathon M., additional, Parikh, Puja B., additional, George, Isaac, additional, Leon, Martin, additional, and Khalique, Omar K., additional
- Published
- 2015
- Full Text
- View/download PDF
106. Transcatheter Valve Implantation in Failed Surgically Inserted Bioprosthesis
- Author
-
Hamid, Nadira B., primary, Khalique, Omar K., additional, Monaghan, Mark J., additional, Kodali, Susheel K., additional, Dvir, Danny, additional, Bapat, Vinayak N., additional, Nazif, Tamim M., additional, Vahl, Torsten, additional, George, Isaac, additional, Leon, Martin B., additional, and Hahn, Rebecca T., additional
- Published
- 2015
- Full Text
- View/download PDF
107. Interventional Echocardiography: Current Role and Progress
- Author
-
Hamid, Nadira, primary and Ewe, See Hooi, additional
- Published
- 2015
- Full Text
- View/download PDF
108. THE EFFECT OF OVERSIZING ON THE HEMODYNAMIC PERFORMANCE OF THE SAPIEN 3 TRANSCATHETER HEART VALVE
- Author
-
Hahn, Rebecca T., primary, Fox, Brendan, additional, Khalique, Omar, additional, Hamid, Nadira, additional, Williams, Mathew, additional, George, Isaac, additional, Nazif, Tamim, additional, Vahl, Torsten, additional, Gada, Hemal, additional, White, Jonathon, additional, Parikh, Puja, additional, Leon, Martin, additional, and Kodali, Susheel, additional
- Published
- 2015
- Full Text
- View/download PDF
109. PM429 Early LV Dysfunction in Stage 3 Chronic Kidney Disease (CKD) Assessed by Stress Based Ventricular Contractility Index
- Author
-
Hamid, Nadira, primary, Le, Thu Thao, additional, Huang, Feiqiong, additional, Chen, Qifeng, additional, Gao, Fei, additional, Suhail, Sufi Muhammad, additional, and San Tan, Ru, additional
- Published
- 2014
- Full Text
- View/download PDF
110. PM080 Diastolic Stiffness As Assessed By Diastolic Wall Strain In Patients With Chronic Kidney Disease
- Author
-
Huang, Feiqiong, primary, Le, Thu Thao, additional, Hamid, Nadira, additional, and Tan, Ru San, additional
- Published
- 2014
- Full Text
- View/download PDF
111. TCT-698 Acute changes in mitral annular geometery after Mitraclip procedure in functional and degenerative mitral regurgitation
- Author
-
Yap, Jonathan, primary, Yeo, Khung Keong, additional, Hamid, Nadira, additional, Lim, Eric, additional, Ting, Peter, additional, Tang, Hak Chiaw, additional, Ewe, See Hooi, additional, and Ding, Zee Pin, additional
- Published
- 2013
- Full Text
- View/download PDF
112. THE ABSENCE OF SEVERE CORONARY STENOSIS (≥70%) ON CORONARY COMPUTED TOMOGRAPHIC ANGIOGRAPHY RELIABLY EXCLUDES MODERATE TO SEVERE ISCHEMIA ON MYOCARDIAL PERFUSION IMAGING
- Author
-
Koh, Huilin, primary, Tan, Swee Yaw, additional, Hamid, Nadira, additional, Chua, Terrance, additional, Allen, John, additional, Ng, Rachel, additional, Keng, Felix, additional, Cheah, Foong Koon, additional, and Chia, Stanley, additional
- Published
- 2012
- Full Text
- View/download PDF
113. Case of Idiopathic Left Ventricular Tachycardia (ILVT)
- Author
-
Hamid, Nadira, primary and Chia, Stanley, additional
- Published
- 2011
- Full Text
- View/download PDF
114. Refractory Hypoxia in Right Ventricular Infarction
- Author
-
Hamid, Nadira, primary and Keng, Felix, additional
- Published
- 2011
- Full Text
- View/download PDF
115. Transcatheter Valve Implantation in Failed Surgically Inserted Bioprosthesis Review and Practical Guide to Echocardiographic Imaging in Valve-in-Valve Procedures
- Author
-
Hamid, Nadira B., Khalique, Omar K., Monaghan, Mark J., Kodali, Susheel K., Dvir, Danny, Bapat, Vinayak N., Nazif, Tamim M., Vahl, Torsten, George, Isaac, Leon, Martin B., and Hahn, Rebecca T.
- Subjects
echocardiography ,TAVR ,biological valve replacement - Abstract
An increased use of bioprosthetic heart valves has stimulated an interest in possible transcatheter options for bioprosthetic valve failure given the high operative risk. The encouraging results of transcatheter aortic valve implantation in high-risk surgical candidates with native disease have led to the development of the transcatheter valve-in-valve (VIV) procedures for failed bioprostheses. VIV procedures are unique in many ways, and there is an increased need for multimodality imaging in a team-based approach. The echocardiographic approach to VIV procedures has not previously been described. In this review, we summarize key echocardiographic requirements for optimal patient selection, procedural guidance, and immediate post-procedural assessment for VIV procedures.
- Full Text
- View/download PDF
116. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study.
- Author
-
Vahl, Torsten P, Thourani, Vinod H, Makkar, Raj R, Hamid, Nadira, Khalique, Omar K, Daniels, David, McCabe, James M, Satler, Lowell, Russo, Mark, Cheng, Wen, George, Isaac, Aldea, Gabriel, Sheridan, Brett, Kereiakes, Dean, Golwala, Harsh, Zahr, Firas, Chetcuti, Stanley, Yadav, Pradeep, Kodali, Susheel K, and Treede, Hendrik
- Subjects
- *
HEART valve prosthesis implantation , *AORTIC valve insufficiency , *PREOPERATIVE risk factors , *AORTIC valve transplantation , *HEART valves - Abstract
Surgery remains the only recommended intervention for patients with native aortic regurgitation. A transcatheter therapy to treat patients at high risk for mortality and complications with surgical aortic valve replacement represents an unmet need. Commercial transcatheter heart valves in pure aortic regurgitation are hampered by unacceptable rates of embolisation and paravalvular regurgitation. The Trilogy transcatheter heart valve (JenaValve Technology, Irvine, CA, USA) provides a treatment option for these patients. We report outcomes with transfemoral transcatheter aortic valve implantation (TAVI) in patients with pure aortic regurgitation using this dedicated transcatheter heart valve. The ALIGN-AR trial is a prospective, multicentre, single-arm study. We recruited symptomatic patients (aged ≥18 years) with moderate-to-severe or severe aortic regurgitation at high risk for mortality and complications after surgical aortic valve replacement at 20 US sites for treatment with the Trilogy transcatheter heart valve. The 30-day composite primary safety endpoint was compared for non-inferiority with a prespecified performance goal of 40·5%. The primary efficacy endpoint was 1-year all-cause mortality compared for non-inferiority with a performance goal of 25%. This trial is registered with ClinicalTrials.gov , NCT 04415047, and is ongoing. Between June 8, 2018, and Aug 29, 2022, we screened 346 patients. We excluded 166 (48%) patients and enrolled 180 (52%) patients with symptomatic aortic regurgitation deemed high risk by the heart team and independent screening committee assessments. The mean age of the study population was 75·5 years (SD 10·8), and 85 (47%) were female, 95 (53%) were male, and 131 (73%) were White. Technical success was achieved in 171 (95%) patients. At 30 days, four (2%) deaths, two (1%) disabling strokes, and two (1%) non-disabling strokes occurred. Using standard Valve Academic Research Consortium-2 definitions, the primary safety endpoint was achieved, with events occurring in 48 (27% [97·5% CI 19·2–34·0]) patients (p non-inferiority <0·0001), with new pacemaker implantation in 36 (24%) patients. The primary efficacy endpoint was achieved, with mortality in 14 (7·8% [3·3–12·3]) patients at 1 year (p non-inferiority <0·0001). This study shows the safety and effectiveness of treating native aortic regurgitation using a dedicated transcatheter heart valve to treat patients with symptomatic moderate-to-severe or severe aortic regurgitation who are at high risk for mortality or complications after surgical aortic valve replacement. The observed short-term clinical and haemodynamic outcomes are promising as are signs of left ventricular remodelling, but long-term follow-up is necessary. JenaValve Technology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
117. Deep Learning Electrocardiographic Analysis for Detection of Left-Sided Valvular Heart Disease.
- Author
-
Elias, Pierre, Poterucha, Timothy J., Rajaram, Vijay, Moller, Luca Matos, Rodriguez, Victor, Bhave, Shreyas, Hahn, Rebecca T., Tison, Geoffrey, Abreau, Sean A., Barrios, Joshua, Torres, Jessica Nicole, Hughes, J. Weston, Perez, Marco V., Finer, Joshua, Kodali, Susheel, Khalique, Omar, Hamid, Nadira, Schwartz, Allan, Homma, Shunichi, and Kumaraiah, Deepa
- Subjects
- *
HEART valve diseases , *DEEP learning , *MITRAL valve insufficiency , *MACHINE learning , *AORTIC valve insufficiency , *RESEARCH , *RESEARCH methodology , *AORTIC stenosis , *EVALUATION research , *COMPARATIVE studies , *ELECTROCARDIOGRAPHY , *RESEARCH funding - Abstract
Background: Valvular heart disease is an important contributor to cardiovascular morbidity and mortality and remains underdiagnosed. Deep learning analysis of electrocardiography (ECG) may be useful in detecting aortic stenosis (AS), aortic regurgitation (AR), and mitral regurgitation (MR).Objectives: This study aimed to develop ECG deep learning algorithms to identify moderate or severe AS, AR, and MR alone and in combination.Methods: A total of 77,163 patients undergoing ECG within 1 year before echocardiography from 2005-2021 were identified and split into train (n = 43,165), validation (n = 12,950), and test sets (n = 21,048; 7.8% with any of AS, AR, or MR). Model performance was assessed using area under the receiver-operating characteristic (AU-ROC) and precision-recall curves. Outside validation was conducted on an independent data set. Test accuracy was modeled using different disease prevalence levels to simulate screening efficacy using the deep learning model.Results: The deep learning algorithm model accuracy was as follows: AS (AU-ROC: 0.88), AR (AU-ROC: 0.77), MR (AU-ROC: 0.83), and any of AS, AR, or MR (AU-ROC: 0.84; sensitivity 78%, specificity 73%) with similar accuracy in external validation. In screening program modeling, test characteristics were dependent on underlying prevalence and selected sensitivity levels. At a prevalence of 7.8%, the positive and negative predictive values were 20% and 97.6%, respectively.Conclusions: Deep learning analysis of the ECG can accurately detect AS, AR, and MR in this multicenter cohort and may serve as the basis for the development of a valvular heart disease screening program. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
118. Acute changes in mitral annular geometery after Mitraclip procedure in functional and degenerative mitral regurgitation.
- Author
-
Yap, Jonathan, Yeo, Khung Keong, Hamid, Nadira, Lim, Eric, Ting, Peter, Tang, Hak Chiaw, Ewe, See Hooi, and Ding, Zee Pin
- Published
- 2013
- Full Text
- View/download PDF
119. UNVEILING OUTCOMES IN COEXISTING SEVERE AORTIC STENOSIS AND TRANSTHYRETIN CARDIAC AMYLOIDOSIS.
- Author
-
Rosenblum, Hannah, Masri, Ahmad Munir, Narotsky, David, Jeff, Goldsmith, Hamid, Nadira, Hahn, Rebecca T., Kodali, Susheel K., Vahl, Torsten, Nazif, Tamim, Khalique, Omar K., Bokhari, Sabahat, Prem, Soman, Cavalcante, Joao L., Maurer, Mathew, and Castano, Adam
- Subjects
- *
CARDIAC amyloidosis , *AORTIC stenosis , *TRANSTHYRETIN , *HEART valve diseases - Published
- 2020
- Full Text
- View/download PDF
120. Impact of Renal and Liver Function on Clinical Outcomes Following Tricuspid Valve Transcatheter Edge-to-Edge Repair.
- Author
-
Jorde UP, Benza R, McCarthy PM, Ailawadi G, Whisenant B, Makkar R, Tadros P, Naik H, Fam N, Sauer AJ, Murthy S, Kar S, von Bardeleben RS, Hahn RT, Hamid N, Zbinden J, Sorajja P, and Adams D
- Abstract
Background: The TRILUMINATE Pivotal trial is a prospective, randomized, controlled study of patients with severe tricuspid regurgitation (TR). Venous congestion due to TR may lead to end-organ dysfunction and failure. The potential to reverse or stop further deterioration in end-organ function is an important goal of treatment., Objectives: This study sought to examine changes in end-organ function after tricuspid transcatheter edge-to-edge repair (TEER) and assess the association of baseline end-organ function with heart failure (HF) hospitalizations and mortality., Methods: Subjects were randomized 1:1 to either the TEER group (TriClip System + medical therapy) or control group (medical therapy alone). Laboratory assessments and TR grading were performed at baseline and at all follow-up visits (discharge, 30 days, 6 months, and 12 months). An independent echocardiography core laboratory assessed TR severity and an independent clinical events committee adjudicated adverse events., Results: A total of 572 subjects were enrolled and randomized (285 TEER, 287 control patients). Patients with moderate-to-severe end-organ impairment (estimated glomerular ejection fraction [eGFR] <45 mL/min/1.73 m
2 or Model for End-Stage Liver Disease excluding INR [MELD-XI] >15) at baseline had increased incidence of HF hospitalization and death through 12 months, regardless of treatment. There were no statistically significant differences between TEER and control patients in eGFR or MELD-XI at 12 months. In subgroup analyses examining only successful TEER patients (moderate or less TR at discharge) compared with control patients, as well as when censoring patients with normal baseline values, both eGFR (+3.55 ± 1.04 mL/min/1.73 m2 vs 0.07 ± 1.10 mL/min/1.73 m2 ; P = 0.022) and MELD-XI (-0.52 ± 0.18 vs 0.34 ± 0.18; P = 0.0007) improved., Conclusions: Baseline end-organ function was associated with HF hospitalization and death in patients with severe TR. At 12 months, eGFR and MELD-XI scores were not statistically significantly different between the overall TEER and control groups. In patients who had successful TEER, statistically significant, yet small, favorable changes occurred for both eGFR and MELD-XI. Further investigation is needed to assess whether these changes in end-organ function after successful TEER are clinically meaningful and reduce HF hospitalization or death. (Clinical Trial to Evaluate Cardiovascular Outcomes In Patients Treated With the Tricuspid Valve Repair System Pivotal [TRILUMINATE Pivotal]; NCT03904147)., Competing Interests: Funding Support and Author Disclosures The TRILUMINATE Pivotal trial was funded and sponsored by Abbott. Dr Jorde has received consulting fees from Abbott and Edwards Lifesciences. Dr Benza has received consulting fees from Abbott and Bayer HealthCare Pharmaceuticals Inc; and has been an endpoint review committee member for United Therapeutics. Dr McCarthy has been a coprincipal investigator of REPAIR-MR (unpaid) for Abbott; has served on advisory boards for Abbott and egnite; has received royalties from Edwards Lifesciences; and has received speaker fees from Medtronic, Edwards Lifesciences, and Atricure. Dr Ailawadi has received consulting fees from Abbott, Edwards Lifesciences, and Medtronic. Dr Whisenant has received consulting fees from Abbott and Edwards Lifesciences. Dr Makkar has received grants and institutional research support from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic; has received consulting fees from Cordis Corporation and Medtronic; and has performed unpaid trial activities for Abbott, Boston Scientific, and Edwards Lifesciences. Dr Tadros has received consulting fees from Abbott and Edwards Lifesciences. Dr Naik has received consulting fees from Abbott, Boston Scientific, and Edwards Lifesciences. Dr Fam has received consulting fees from Abbott. Dr Sauer has received grants and institutional research support from Saint Luke’s Mid America Heart Institute, Bayer, CSL Vifor, Pfizer, Rivus, AstraZeneca, Novo Nordisk, Impulse Dynamics, 35Pharma, Abbott, Boston Scientific, General Prognostics, Acorai, Story Health, and Amgen; and has received honoraria for speaking or advising from Bayer, CSL Vifor, Abbott, Impulse Dynamics, Boston Scientific, Edwards Lifesciences, Acorai, Story Health, and General Prognostics. Dr Kar has received consulting fees from Abbott, Boston Scientific, InterShunt, Medtronic, Peija, V-Wave, W.L. Gore, and Medtronic; and has served as co-principal investigator of the EXPAND and REPAIR MR trials for Abbott. Dr von Bardeleben has performed unpaid trial activities for Abbott, Edwards Lifesciences, and University of Göttingen (IIT); and has served on advisory boards or speakers bureaus for Abbott, Bioventrix, Boston Scientific, Cardiac Dimensions, Edwards Lifesciences, and NeoChord. Dr Hahn has received speaker fees from Abbott, Baylis Medical Company Inc, Edwards Lifesciences, Medtronic, and Philips. Dr Hamid has received consulting fees from 4C Medical Technologies, Inc, Alleviant Medical, Inc, AMX, Anteris Technologies Corporation, Edwards Lifesciences, Philips, Valcare Med Ltd, VDyne, and W.L. Gore & Associates, Inc. Dr Zbinden has been a senior clinical scientist for Abbott. Dr Sorajja is co-principal investigator for the TRILUMINATE Pivotal trial; has served on advisory boards for Anteris Technologies and VDyne; and has received consulting fees from Boston Scientific, Edwards Lifesciences, Evolution Medical, Medtronic, Shifamed, TriFlo, and W.L. Gore & Associates, Inc. Dr Adams is co-principal investigator for the TRILUMINATE Pivotal trial; and receives royalties from Edward Lifesciences and Medtronic. Dr Murthy has reported that she has no relationships relevant to the contents of this paper to disclose., (Copyright © 2024. Published by Elsevier Inc.)- Published
- 2024
- Full Text
- View/download PDF
121. Impact of Interventricular Interaction on Ventricular Function: Insights From Right Ventricular Pressure-Volume Analysis.
- Author
-
Brener MI, Kanwar MK, Lander MM, Hamid NB, Raina A, Sethi SS, Finn MT, Fried JA, Raikhelkar J, Masoumi A, Rosenblum HR, Maurer MS, Sayer G, Burkhoff D, and Uriel N
- Subjects
- Humans, Male, Middle Aged, Female, Heart Ventricles physiopathology, Ventricular Dysfunction, Right physiopathology, Ventricular Pressure physiology, Aged, Adult, Hemodynamics physiology, Heart-Assist Devices, Ventricular Function, Right physiology, Stroke Volume physiology, Heart Failure physiopathology, Heart Failure therapy
- Abstract
Background: Interventricular interactions may be responsible for the decline in ventricular performance observed in various disease states that primarily affect the contralateral ventricle., Objectives: This study sought to quantify the impact of such interactions on right ventricular (RV) size and function using clinically stable individuals with left ventricular assist devices (LVADs) as a model for assessing RV hemodynamics while LV loading conditions were acutely manipulated by changing device speed during hemodynamic optimization studies (ie, ramp tests)., Methods: The investigators recorded RV pressure-volume loops with a conductance catheter at various speeds during ramp tests in 20 clinically stable HeartMate3 recipients., Results: With faster LVAD speeds and greater LV unloading, indexed RV end-diastolic volume increased (72.28 ± 15.07 mL at low speed vs 75.95 ± 16.90 at high speed; P = 0.04) whereas indexed end-systolic volumes remained neutral. This resulted in larger RV stroke volumes and shallower end-diastolic pressure-volume relationships. Concurrently, RV end-systolic pressure decreased (31.58 ± 9.75 mL at low speed vs 29.58 ± 9.41 mL at high speed; P = 0.02), but contractility, as measured by end-systolic elastance, did not change significantly. The reduction in RV end-systolic pressure was associated with a reduction in effective arterial elastance from 0.65 ± 0.43 mm Hg/mL at low speed to 0.54 ± 0.33 mm Hg/mL at high speed (P = 0.02)., Conclusions: Interventricular interactions resulted in improved RV compliance, diminished afterload, and did not reduce RV contractility. These data challenge the prevailing view that interventricular interactions compromise RV function, which has important implications for the understanding of RV-LV interactions in various disease states, including post-LVAD RV dysfunction., Competing Interests: Funding Support and Author Disclosures This project was supported, in part, by the American College of Cardiology and Merck Research Fellowship Award. Dr Brener has received consulting fees from Artract Medical and Osprey Medical. Dr Kanwar has served on the Medical Advisory Boards of Abiomed, CareDx, and CorWave. Dr Lander has served on the Medical Advisory Board of Abiomed. Dr Raina has received research support from United Therapeutics and Merck. Dr Sethi has received honoraria from Janssen and Chiessi; and has received institutional grant support from the American Heart Association’s COVID-19 Rapid Response Award. Dr Maurer has received funding from the National Institutes of Health (HL139671-01AL1 and AG K24AG036778); AD consulting income from Ionis, Alnylam, Eidos Therapeutics, Pfizer, Intellia, and Prothena; and his institution has also received funding for clinical trials for Ionis, Alnylam, Eidos Therapeutics, Pfizer, and Attralus. Dr Sayer has received consulting fees from Abbott. Dr Burkhoff has received an unrestricted institutional educational grant from Abiomed. Dr Uriel has received grant support from Abbott, Abiomed, and Fire1; and has served on the Medical Advisory Boards of Leviticus and Revamp. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
122. Degenerative Mitral Regurgitation Outcomes in Asian Compared With European-American Institutions.
- Author
-
Hamid N, Bursi F, Benfari G, Vanoverschelde JL, Tribouilloy C, Biagini E, Avierinos JF, Barbieri A, Fan Y, Guerra F, Leng CY, Essayagh B, Pasquet A, Szymansky C, Théron A, Michelena HI, Nkomo VT, Vancraeynest D, Rusinaru D, Grigioni F, Enriquez-Sarano ML, Pin DZ, and Pui-Wai Lee A
- Abstract
Background: Clinical outcome and interventional thresholds for degenerative mitral regurgitation (DMR) were developed in studies of patients at European and American institutions (EAIs), but little is known about patients at Asian institutions (AsIs)., Objectives: This study sought to contrast DMR presentation/management/outcomes of AsI patients vs EAI patients., Methods: Patients with DMR due to flail leaflet from Hong Kong and Singapore (AsI cohort, n = 737) were compared with EAI patients (n = 682) enrolled in the MIDA (Mitral regurgitation International Database) registry with similar eligibility criteria., Results: AsI patients presented similar DMR lesion/consequences vs EAI patients, but they were younger, with fewer symptoms (74% vs 44% Class I), more sinus rhythm (83% vs 69%), and lower EuroSCORE II (European System for Cardiac Operative Risk Evaluation II) (0.9 ± 0.5 vs 1.4 ± 1.5; all P < 0.0001). Imaging showed smaller absolute left atrial/ventricular dimensions in AsI patients, belying cardiac dilatation with larger body surface area-indexed diameters (all P < 0.01). Surgical/interventional mitral repair was similarly predominant (90% vs 91%; P = 0.47), and early repair was similarly beneficial (for AsI patients, adjusted HR: 0.28; 95% CI: 0.16-0.49; for EAI patients, HR: 0.32; 95% CI: 0.20-0.49; both P < 0.0001). However, AsI patients underwent fewer interventions (55% ± 2% vs 77% ± 2% at 1 year; P < 0.0001) and incurred excess mortality (adjusted HR: 1.60 [95% CI: 1.13-2.27] vs EAI patients; P = 0.008) at long-term postdiagnosis. Propensity score matching (434 patient pairs), which balanced all clinical characteristics, confirmed that there was undertreatment and excess mortality in the long term in AsI patients with DMR ( P < 0.0001)., Conclusions: Imaging may underestimate volume overload in AsI patients due to smaller cardiac cavities related to smaller body size compared with EAI patients with similar mitral lesions and DMR severity. AsI patients enjoy similar mitral repair predominance and early intervention benefits but undergo fewer mitral interventions than EAI patients and incur subsequent excess mortality, suggesting the need to account for imaging and cultural specificity to improve DMR outcomes worldwide., Competing Interests: Dr Enriquez-Sarano has received personal fees from Edwards LLC, ChemImage Inc, and CryoLife Inc, outside the submitted work. Dr Ding has received personal fees from GE Healthcare; and nonfinancial support from Phillips Healthcare, outside the submitted work. Dr Lee has received grant support from Abbott, outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
123. Tricuspid Valve Leaflets-Lead Interaction: Adjunctive Role of Functional Cardiac Computed Tomography for Clinical Decision Making.
- Author
-
Margonato D, Enriquez-Sarano M, Wang C, Phichaphop A, Okada A, Koike H, Fukui M, Hamid N, Lesser J, Sorajja P, Bapat V, and Cavalcante JL
- Abstract
The diagnostic approach toward the management of cardiac implantable electronic device-related tricuspid regurgitation is challenging and undefined. Functional cardiac computed tomography angiography provides a complementary role to echocardiography in the evaluation of lead-leaflet interaction which can help the clinical decision-making process, as presented in this case series., Competing Interests: Dr Enriquez-Sarano has received consulting fees from CryoLife, Edwards Lifesciences, HighLife, and ChemImage. Dr Sorajja has received consulting fees from 4C Medical, Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Evolution Medical, Foldax, GLG, Medtronic, Philips, Siemens, Shifamed, W.L. Gore & Associates, VDyne, and xDot Medical; and has received institutional research grant support from Abbott Structural, Medtronic, and Boston Scientific. Dr Bapat has received consulting fees from Abbott Structural, Medtronic, Boston Scientific, Edwards Lifesciences, 4C Medical, and Anteris. Dr Cavalcante has received consulting fees from 4C Medical, Abbott Structural, Anteris, Aria CV, Boston Scientific, Edwards Lifesciences, HighLife, Medtronic, VDyne, W.L. Gore & Associates, and Xylocor; and has received research grant support from Abbott Northwestern Hospital Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2024 The Authors.)
- Published
- 2024
- Full Text
- View/download PDF
124. Percutaneous Mechanical Aspiration in Infective Endocarditis: Applications, Technical Considerations, and Future Directions.
- Author
-
El Sabbagh A, Yucel E, Zlotnick D, Moriarty JM, Younes S, Hamid N, Akhtar Y, Baddour LM, O'Gara P, Starck C, Bangalore S, Parikh SA, Rosenfield K, and Sethi SS
- Abstract
In recent years, there has been a shift in the epidemiology of patients with infective endocarditis (IE). This has been characterized by an alarming increase in IE in patients who inject drugs, cardiac implantable electronic device-related IE, and those with comorbid conditions and high surgical risk. This unmet need has mandated a reevaluation of complex management strategies in these patients and introduction of unconventional approaches in treatment. Percutaneous mechanical aspiration has emerged as both a diagnostic and therapeutic option in selected patients with IE. In this review, the authors discuss the gaps in care of IE, rationale, device armamentarium, procedural, and technical considerations and applications of percutaneous mechanical aspiration in IE., Competing Interests: David Zlotnick is on the speaker’s bureau for Abiomed, Inari Medical. John Moriarty consults for AngioDynamics, Penumbra Medical, Innova Vascular, Pavmed, Pfizer, and Boston Scientific. Nadira Hamid consults for Abbott Structural, Anteris, AMX, 4C Medical Technologies, Alleviant Medical, Edwards Lifesciences, Philips, GE, Valcare Med, VDyne, and WL Gore. Yasir Akhtar received honoraria and is on speaker bureau for AngioDynamics and Penumbra. Kenneth Rosenfield consults for and/or is on the scientific advisory board member for Althea Medical, AngioDynamics, Boston Scientific, Contego, InspireMD, Magneto, Mayo Clinic, Neptune Medical, Philips, Summa Therapeutics, SurModics, Thrombolex, Terumo, and Truvic; holds equity in Accolade, Access Vascular, Aerami, Althea Medical, Contego, Cruzar Systems, Embolitech, Endospan, InspireMD, JanaCare, Magneto, Orchestra BioMed, PQ Bypass, Prosomnus, Shockwave Medical, Summa Therapeutics, Thrombolex, Truvic, and Valcare; and is a board member for National PERT Consortium. Christoph Starck received honoraria, consults for, and is on the advisory board of AngioDynamics, Abiomed, Atricure, Medtronic, Spectranetics, Biotronik, LivaNova (Sorin), and Cook Medical and received departmental or institutional research funding from Cook Medical and Hylomorph. Sripal Bangalore is on the advisory board for Abbott Vascular, Boston Scientific, Biotronik, Amgen, Pfizer, Merck, REATA, Inari Medical, and Truvic. Sahil Parikh receives institutional grants/research support from Abbott Vascular, Shockwave Medical, TriReme Medical, SurModics, Silk Road Medical, and the National Institutes of Health; has received consulting fees from Terumo and Abiomed; and has served on the advisory boards of Abbott, Medtronic, Boston Scientific, CSI, Janssen, and Philips. Sanjum Sethi reports honoraria from Janssen and Chiesi. Abdallah Sabbagh, Evin Yucel, Stephanie Younes, Larry Baddour, and Patrick O’Gara reported no financial interests., (© 2023 The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
125. Tricuspid Regurgitation: From Imaging to Clinical Trials to Resolving the Unmet Need for Treatment.
- Author
-
Grapsa J, Praz F, Sorajja P, Cavalcante JL, Sitges M, Taramasso M, Piazza N, Messika-Zeitoun D, Michelena HI, Hamid N, Dreyfus J, Benfari G, Argulian E, Chieffo A, Tchetche D, Rudski L, Bax JJ, Stephan von Bardeleben R, Patterson T, Redwood S, Bapat VN, Nickenig G, Lurz P, Hausleiter J, Kodali S, Hahn RT, Maisano F, and Enriquez-Sarano M
- Subjects
- Humans, Diagnostic Imaging, Predictive Value of Tests, Treatment Outcome, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Clinical Trials as Topic, Heart Valve Prosthesis Implantation, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery
- Abstract
Tricuspid regurgitation (TR) is a highly prevalent and heterogeneous valvular disease, independently associated with excess mortality and high morbidity in all clinical contexts. TR is profoundly undertreated by surgery and is often discovered late in patients presenting with right-sided heart failure. To address the issue of undertreatment and poor clinical outcomes without intervention, numerous structural tricuspid interventional devices have been and are in development, a challenging process due to the unique anatomic and physiological characteristics of the tricuspid valve, and warranting well-designed clinical trials. The path from routine practice TR detection to appropriate TR evaluation, to conduction of clinical trials, to enriched therapeutic possibilities for improving TR access to treatment and outcomes in routine practice is complex. Therefore, this paper summarizes the key points and methods crucial to TR detection, quantitation, categorization, risk-scoring, intervention-monitoring, and outcomes evaluation, particularly of right-sided function, and to clinical trial development and conduct, for both interventional and surgical groups., Competing Interests: Funding Support and Author Disclosures Dr Praz has received travel expenses from Edwards Lifesciences, Abbott Vascular, Polares Medical, and Medira. Dr Sorajja has served as a consultant for 4C Medical, Abbott Structural, Boston Scientific, Edwards Lifesciences, Foldax, GE Medical, Medtronic, Philips, Shifamed, Siemens, WL Gore, vDyne, and xDot. Dr Cavalcante has received consulting fees/honoraria from Abbott Structural, Anteris, AriaCV, Boston Scientific, Edwards Lifesciences, Medtronic, VDyne, WL Gore, and Xylocor; and has received research grants from Abbott Northwestern Hospital Foundation and Abbott Structural. Dr Sitges has received speaker honoraria and consultant fees for Abbott, Edwards Lifesciences, Medtronic, and General Electric. Dr Taramasso has acted as a consultant and/or received consultancy fees from Abbott, Edwards Lifescience, Boston Scientific, Medtronic, Shenqi Medical, MEDIRA, Cardiovalve, VentriMend, Simulands, MTEx, Occlufit, CoreMedic, and HeD Imaging; has received an institutional educational grant from Edwards Lifescience and Abbott; and has served on the advisory board for Abbott. Dr Messika-Zeitoun has received research grant from Edwards Lifesciences. Dr Dreyfus has served as a proctor for Abbott. Dr Rudski has small holding of shares in General Electric. Dr Bax has received lecture fees from Abbott and Edwards Lifesciences; and has received unrestricted research grants from Edwards Lifesciences and Abbott. Dr Stephan von Bardeleben has received research support for trials from Abbott, Edwards Lifesciences, Jenavalve, Jenscare, Medtronic, and Neochord. Dr Redwood has served as a proctor and received speaker fees from Edwards; he has also served as on the international advisory board member for Medtronic. Dr Bapat has served as a consultant with Edwards Lifescienes, Medtronic, and Abbott; and has received a research grant from Atricure. Dr Nickenig has received honoraria for lectures or advisory boards from Abbott, Cardiovalve, Edwards, Medtronic, and Boston Scientific. Dr Hausleiter has received research support from Edwards Lifesciences. Dr Hahn has received speaker fees from Abbott Structural, Baylis Medical, Edwards Lifesciences, and Philips Healthcare; has institutional consulting contracts for which she receives no direct compensation with Abbott Structural, Boston Scientific, Edwards Lifesciences, Medtronic, and Novartis; she is Chief Scientific Officer for the Echocardiography Core Laboratory at the Cardiovascular Research Foundation for multiple industry-sponsored trials, for which she receives no direct industry compensation. Dr Maisano has received grant and/or research institutional support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific Corporation, NVT, and Terumo; has received consulting fees, honoraria personal and institutional from Abbott, Medtronic, Edwards Lifesciences, Xeltis, Cardiovalve, Occlufit, Simulands, and Mtex; has received royalty income rights from Edwards Lifesciences; and is a shareholder (including share options) of Cardiogard, Cardiovalve, Magenta, SwissVortex, Transseptalsolutions, 4Tech, and Perifect. Dr Enriquez-Sarano has received consulting fees from Artivion, ChemImage, Edwards Lifescience, HighLife, and Corcym. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
126. Deformation of transcatheter heart valves with mitral valve-in-valve.
- Author
-
Fukui M, Okada A, Burns MR, Sato H, Thao KR, Wang C, Koike H, Hamid N, Enriquez-Sarano M, Lesser JR, Cavalcante JL, Sorajja P, and Bapat VN
- Subjects
- Humans, Mitral Valve diagnostic imaging, Mitral Valve surgery, Treatment Outcome, Prosthesis Design, Aortic Valve surgery, Aortic Valve Stenosis surgery, Heart Valve Prosthesis, Transcatheter Aortic Valve Replacement
- Abstract
Background: The use of oversizing in mitral valve-in-valve (MViV) procedures can lead to non-uniform expansion of transcatheter heart valves (THV). This may have implications for THV durability., Aims: The objective of this study was to assess the extent and predictors of THV deformation in MViV procedures., Methods: We examined 33 patients who underwent MViV with SAPIEN prostheses. The extent of THV deformation (deformation index, eccentricity, neosinus volume, asymmetric leaflet expansion and vertical deformation) and hypoattenuating leaflet thickening (HALT) were assessed using cardiac computed tomography (CT), performed prospectively at 30 days post-procedure. For descriptive purposes, the THV deformation index was calculated, with values >1.00 representing a more hourglass shape., Results: Non-uniform underexpansion of THV was common after MViV implantation, with a median expansion area of 74.0% (interquartile range 68.1-84.1) at the narrowest level and a THV deformation index of 1.21 (1.13-1.29), but circularity was maintained with eccentricity ranging from 0.24 to 0.28. The degree of oversizing was a key factor associated with greater underexpansion and a higher deformation index (β=-0.634; p<0.001; β=0.594; p<0.001, respectively). Overall, the incidence of HALT on the 30-day postprocedural CT was 27.3% (9 of 33). Most patients (32 of 33) were on anticoagulation therapy, but the prothrombin time and international normalised ratio (PT-INR) at the time of the CT scan was <2.5 in 23 of 32 patients. Among patients with a PT-INR of <2.5, HALT was predominantly observed with a high THV deformation index of ≥1.18., Conclusions: THV deformation, i.e., underexpansion and an hourglass shape, commonly occurs after MViV implantation and is negatively affected by excessive oversizing. Optimising THV expansion during MViV could potentially prevent HALT.
- Published
- 2023
- Full Text
- View/download PDF
127. First-in-human description of a novel transcatheter tricuspid valve prosthesis to preserve the asymmetric shape of the right ventricle.
- Author
-
Sorajja P, Gorgorishvili I, Burns M, Buysschaert I, Debonnaire P, Van der Heyden J, and Hamid N
- Published
- 2023
- Full Text
- View/download PDF
128. Early safety and feasibility of a first-in-class biomimetic transcatheter aortic valve - DurAVR.
- Author
-
Kodali SK, Sorajja P, Meduri CU, Feldt K, Cavalcante JL, Garg P, Hamid N, Poon KK, Settergren MRM, Burns MR, Rück A, Sathananthan J, Zajarias A, Shaburishvili T, Zirakashvili T, Zhividze M, Katchakhidze G, and Bapat VN
- Subjects
- Humans, Female, Aged, Aged, 80 and over, Male, Aortic Valve diagnostic imaging, Aortic Valve surgery, Prospective Studies, Feasibility Studies, Biomimetics, Treatment Outcome, Prosthesis Design, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods, Aortic Valve Stenosis surgery, Heart Valve Prosthesis
- Abstract
Background: TAVI is a widely accepted treatment for patients with severe aortic stenosis (AS). Despite the adoption of diverse therapies, opportunities remain to develop technologies tailored to provide optimal acute and potential long-term benefits, particularly around haemodynamics, flow and durability., Aims: We aimed to evaluate the safety and feasibility of the DurAVR transcatheter heart valve (THV), a first-in-class biomimetic valve, in the treatment of patients with symptomatic severe AS., Methods: This was a first-in-human (FIH), prospective, non-randomised, single-arm, single-centre study. Patients with severe, symptomatic AS of any surgical risk and who were eligible for the DurAVR THV prosthesis were recruited; they were assessed at baseline, 30 days, 6 months, and 1 year post-procedure for implant success, haemodynamic performance, and safety., Results: Thirteen patients (73.9±6.4 years old, 77% female) were enrolled. The DurAVR THV was successfully implanted in 100% of cases with no device-related complications. One access site complication, one permanent pacemaker implantation, and one case of moderate aortic regurgitation occurred. Otherwise, no deaths, stroke, bleeding, reinterventions, or myocardial infarction were reported during any of the follow-up visits. Despite a mean annulus size of 22.95±1.09 mm, favourable haemodynamic results were observed at 30 days (effective orifice area [EOA] 2.00±0.17 cm
2 , and mean pressure gradient [MPG] 9.02±2.68 mmHg) and were sustained at 1 year (EOA 1.96±0.11 cm2 , MPG 8.82±1.38 mmHg), resulting in zero patients with any degree of prosthesis-patient mismatch. Additionally, new valve performance measures derived from cardiovascular magnetic resonance displayed restoration of laminar flow, consistent with a predisease state, in conjunction with a mean coaptation length of 8.3±1.7 mm., Conclusions: Preliminary results from the FIH study with DurAVR THV demonstrate a good safety profile with promising haemodynamic performance sustained at 1 year and restoration of near-normal flow dynamics. Further clinical investigation is warranted to evaluate how DurAVR THV may play a role in addressing the challenge of lifetime management in AS patients.- Published
- 2023
- Full Text
- View/download PDF
129. Transcatheter Left Ventricular Restoration in Patients With Heart Failure.
- Author
-
Hamid N, Jorde UP, Reisman M, Latib A, Lim DS, Joseph SM, Kurlianskaya A, Polonetsky O, Neuzil P, Reddy V, Foerst J, Gada H, Grubb KJ, Silva G, Kereiakes D, Shreenivas S, Pinney S, Davidavicius G, Sorajja P, Boehmer JP, Kleber FX, Perier P, VAN Mieghem NM, Dumonteil N, Leon MB, and Burkhoff D
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Ventricular Remodeling, Cardiomyopathies, Heart Failure diagnosis, Heart Failure therapy, Mitral Valve Insufficiency diagnostic imaging, Mitral Valve Insufficiency surgery, Ventricular Dysfunction, Left
- Abstract
Background: Left ventricular (LV) volume reshaping reduces myocardial wall stress and may induce reverse remodeling in patients with heart failure with reduced ejection fraction. The AccuCinch Transcatheter Left Ventricular Restoration system consists of a series of anchors connected by a cable implanted along the LV base that is cinched to the basal free wall radius. We evaluated the echocardiographic and clinical outcomes following transcatheter left ventricular restoration., Methods and Results: We analyzed 51 heart failure patients with a left ventricular ejection fraction between 20% and 40%, with no more than 2+ mitral regurgitation treated with optimal medical therapy, who subsequently underwent transcatheter left ventricular restoration. Serial echocardiograms, Kansas City Cardiomyopathy Questionnaire scores, and 6-minute walk test distances were measured at baseline through 12 months. Primary analysis end point was change in end-diastolic volume at 12 months compared with baseline. Patients (n = 51) were predominantly male (86%) with a mean age of 56.3 ± 13.1 years. Fluoroscopy showed LV free wall radius decreased by a median of 9.2 mm amounting to a 29.6% decrease in the free wall arc length. At 12 months, the LV end-diastolic volume decreased by 33.6 ± 34.8 mL (P < .01), with comparable decreases in the LV end-systolic volume. These decreases were associated with significant improvements in the overall Kansas City Cardiomyopathy Questionnaire score (16.4 ± 18.7 points; P < .01) and 6-minute hall walk test distance (45.9 ± 83.9 m; P < .01). There were no periprocedural deaths; through the 1-year follow-up, 1 patient died (day 280) and 1 patient received a left ventricular assist device (day 13)., Conclusions: In patients with heart failure with reduced ejection fraction without significant mitral regurgitation receiving optimal medical therapy, the AccuCinch System resulted in decreases of LV volume, as well as improved quality of life and exercise endurance. A randomized trial is ongoing (NCT04331769)., Competing Interests: Conflicts of Interest Nadira Hamid reports Institutional grant support. Ulrich Jorde reports travel support from Ancora Heart. Mark Reisman reports travel support from Ancora Heart. Azeem Latib has nothing to declare. D. Scott Lim has nothing to declare. Susan Joseph has nothing to declare. Alena Kurlianskaya has nothing to declare. Oleg Polonetsky, MD, reports consultancy fees from Ancora Heart, and consultancy or proctoring fees from Edwards Lifesciences and Medtronic. Petr Neuzil has nothing to declare. Vivek Reddy has nothing to declare. Jason Foerst has nothing to declare. Hemal Gada has nothing to declare. Kendra J. Grubb reports advisory board and consulting fees for Medtronic, Boston Scientific, Abbott, Ancora, 4C Medical, and honorarium for Edwards Lifesciences. Guilherme Silva has nothing to declare. Dean Kereiakes has nothing to declare. Satya Shreenivas has nothing to declare. Sean Pinney reports consulting fees from Abbott, CareDx, Medtronic, Procyrion, and Transmedics. Giedrius Davidavicius is a consultant to Ancora Heart. Paul Sorajja has nothing to declare. John Boehmer has nothing to declare. Franz X. Kleber is a consultant to Ancora Heart. Patrick Perier has nothing to declare. Nicolas M. Van Mieghem reports research grant support from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, PulseCath BV, Abiomed, Siemens, and Daiichi Sankyo. Nicolas Dumonteil reports consultancy fees from Ancora Heart, is the co-PI of the CorCinch European study; and reports consultancy and proctoring fees from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic. Martin B. Leon reports institutional clinical research grants from Abbott, Abiomed, Ancora, Boston Scientific, Edwards, and Medtronic. Daniel Burkhoff reports institutional grant support from Ancora Heart to the Cardiovascular Research Foundation., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
130. Deformation of Transcatheter Heart Valve Following Valve-in-Valve Transcatheter Aortic Valve Replacement: Implications for Hemodynamics.
- Author
-
Fukui M, Sorajja P, Cavalcante JL, Thao KR, Okada A, Sato H, Wang C, Koike H, Hamid N, Enriquez-Sarano M, Lesser JR, and Bapat VN
- Subjects
- Humans, Aortic Valve diagnostic imaging, Aortic Valve surgery, Treatment Outcome, Prosthesis Design, Hemodynamics, Transcatheter Aortic Valve Replacement adverse effects, Transcatheter Aortic Valve Replacement methods, Bioprosthesis, Heart Valve Prosthesis, Heart Valve Prosthesis Implantation adverse effects, Heart Valve Prosthesis Implantation methods, Aortic Valve Stenosis diagnostic imaging, Aortic Valve Stenosis surgery, Aortic Valve Stenosis etiology
- Abstract
Background: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) may be associated with adverse hemodynamics, which might affect clinical outcomes., Objectives: This study sought to evaluate the extent and predictors of transcatheter heart valve (THV) deformity in ViV TAVR and the relation to postprocedural hemodynamics., Methods: We examined 53 patients who underwent ViV TAVR in surgical heart valves with self-expanding Evolut prostheses. THV deformation was examined using cardiac computed tomography prospectively performed 30 days after ViV TAVR, and correlated with 30-day echocardiographic hemodynamic data., Results: Near complete expansion of the functional portion of the implanted ViV prostheses (ie, >90%) was observed in 16 (30.2%) patients. Factors related to greater expansion of the functional portion and consequently larger neosinus volume were absence of polymer surgical frame, higher implantation and use of balloon aortic valvuloplasty or bioprosthetic valve fracture during the procedure (all P < 0.05). Underexpansion of the functional portion, but not the valve inflow frame, was closely associated with mean gradient and effective orifice area at 30 days on echocardiography, with and without adjustment for the sizes of the THV and surgical heart valve., Conclusions: Underexpansion of the functional portion of THV prostheses is common during ViV TAVR, occurs more frequently with deep implantation and the presence of a polymer surgical stent frame, and is associated with worse postprocedural hemodynamics. Procedural techniques, such as higher implantation and balloon postdilatation, may be used to help overcome problems with THV underexpansion and improve clinical outcomes., Competing Interests: Funding Support and Author Disclosures Dr Sorajja has received consulting fees from 4C Medical, Abbott Structural, Anteris, Boston Scientific, Edwards Lifesciences, Evolution Medical, Foldax, GLG, Medtronic, Phillips, Siemens, Shifamed, WL Gore, vDyne, and xDot; and received institutional research grant support from Abbott Structural, Medtronic, and Boston Scientific. Dr Cavalcante has received consulting fees from 4C, Abbott Structural, Anteris, AriaCV, Boston Scientific, Edwards Lifesciences, HighLife, Medtronic, VDyne, WL Gore, and Xylocor; and received research grant support from the Abbott Northwestern Hospital Foundation. Dr Enriquez-Sarano has received consulting fees from CryoLife, Edwards Lifesciences, Highlife, and ChemImage. Dr Bapat has received consulting fees from Abbott Structural, Medtronic, Boston Scientific, and Edwards Lifesciences. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
131. Cardiac Computed Tomography Angiography Anatomical Characterization of Patients Screened for a Dedicated Transfemoral Transcatheter Valve System for Primary Aortic Regurgitation.
- Author
-
Gogia S, Vahl TP, Thourani VH, Yadav PK, George I, Kodali SK, Hamid N, Ranard L, Chen T, Matsumura M, Maehara A, Treede H, Baldus S, Daniels D, Sheridan BC, Zahr F, Russo MJ, McCabe JM, Chetcuti SJ, Leon MB, Makkar RR, and Khalique OK
- Abstract
Background: Cardiac computed tomography angiography was used to identify anatomical characteristics of the aortic root in patients with severe aortic regurgitation (AR) as compared to those with aortic stenosis (AS) to judge feasibility of transcatheter aortic valve replacement (TAVR) with the JenaValve Trilogy system., Methods: Cardiac computed tomography angiography was performed prior to planned TAVR for 107 patients with severe AR and 92 patients with severe AS. Measurements related to aortic root and coronary artery anatomy were obtained and compared between groups. Perimeter >90 mm and aortic annulus angle >70 degrees were defined as the theoretical exclusion criteria for TAVR. A combination of sinus of Valsalva diameter <30 mm and coronary height <12 mm was defined as high risk for coronary occlusion., Results: The mean age of patients in the AR group was 74.9 ± 11.2 years, 46% were women, and the mean Society of Thoracic Surgeons risk score for mortality was 3.6 ± 2.1. Comparatively, the mean age of patients in the AS group was 82.3 ± 5.53 years, 65% were women, and the mean Society of Thoracic Surgeonsrisk score was 5.5 ± 3.3. Annulus area, perimeter, diameter, and angle were larger in patients with severe AR. Sinus of Valsalva diameters and heights were larger in patients with severe AR. More AR patients were excluded based on perimeter (14 vs. 2%) and annulus angle (6 vs. 1%). More AS patients exhibited high-risk anatomy for left main coronary occlusion (21 vs. 7%) and right coronary occlusion (14 vs. 3%). The maximum dimension of the ascending aorta was larger in patients with severe AR (39 vs. 35 mm). The percentage of referred AR patients with significant aortopathy requiring surgical intervention was very low (only 1 AR patient with ascending aorta diameter >5.5 cm)., Conclusions: A significantly larger proportion of patients with severe AR are excluded from TAVR as compared to AS due to large aortic annulus size and steep annulus angulation. By far the most prevalent excluding factor is aortic annulus size, with fewer patients excluded due to angulation. AR patients have lower-risk anatomy for coronary occlusion. Larger transcatheter valve sizes and further delivery system modifications are required to treat a larger proportion of AR patients., Competing Interests: Dr. George is a consultant for Durvena, Cardiomech, Vdyne, Valcare Medical, Atricure, Zimmer Biomet, MITrx, Mitremedical and has institutional grants from Edwards, Medtronic, Abbott. Dr. Khalique is a consultant for Edwards, Abbott Structural, Triflo, Cardiac Implants, Restore Medical, and Croivalve and is a member of a corelab (he receives no direct industry compensation) with contracts with Ancora, Jenavalve, Atricure, and Abbott Structural and holds equity in Triflo and Cardiac Implants. Dr. Vahl reports institutional funding to Columbia University Medical Center from Abbott, Boston Scientific, Edwards, Jenavalve, and Medtronic, and has received consulting fees from 4D Medical Technologies and Baylis Medical. Dr. Chen is a member of a corelab (she receives no direct industry compensation) with contracts with Ancora and Jenavalve and is a consultant for Intrinsic Imaging, LLC. Dr. McCabe is a consultant for Edwards, Boston Scientific, Medtronic and CSI and holds equity in ConKay Medical and Excision Medical. Vinod Thourani is a medical advisor for Edwards, is a national PI for the Jenavalve Pivotal trial, and is co-founder of Apica cardiovascular. Dr. Treede reports consulting fees from TRICARES. Dr. Baldus reports honoraria from Edwards and Abbott, and a research grant from Abbott. Dr. Zahr reports institutional research support from Edwards and Medtronic. Dr. Russo reports honoraria from Edwards and Abbott. Dr. Leon has received institutional grants from Abbott, Boston Scientific, Edwards, Jenavalve, and Medtronic and holds equity in Valve Medical, Picardia, and Venus MedTech. Dr. Makkar received grant support from Edwards and is a consultant for Abbott, Cordis, and Medtronic., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
132. FEops HEARTguide Patient-Specific Computational Simulations for WATCHMAN FLX Left Atrial Appendage Closure: A Retrospective Study.
- Author
-
Ranard LS, Vahl TP, Sommer R, Ng V, Leb J, Lehenbauer K, Sitticharoenchai P, Khalique O, Hamid N, De Beule M, Bavo A, and Hahn RT
- Abstract
Background: Three-dimensional transesophageal echocardiography (3D-TEE) is the primary imaging tool for left atrial appendage closure planning. The utility of cardiac computed tomography angiography (CCTA) and patient-specific computational models is unknown., Objectives: The purpose of this study was to evaluate the accuracy of the FEops HEARTguide patient-specific computational modeling in predicting appropriate device size, location, and compression of the WATCHMAN FLX compared to intraprocedural 3D-TEE., Methods: Patients with both preprocedural and postprocedural CCTA and 3D-TEE imaging of the LAA who received a WATCHMAN FLX left atrial appendage closure device were studied (n = 22). The FEops HEARTguide platform used baseline CCTA imaging to generate a prediction of device size(s), device position(s), and device dimensions. Blinded (without knowledge of implanted device size/position) and unblinded (implant device size/position disclosed) simulations were evaluated., Results: In 16 (72.7%) patients, the blind simulation predicted the final implanted device size. In these patients, the 3D-TEE measurements were not significantly different and had excellent correlation (Pearson correlation coefficient (r) ≥ 0.90). No patients had peridevice leak after device implant. In the 6 patients for whom the model did not predict the implanted device size, a larger device size was ultimately implanted as per operator preference. The model measurements of the unblinded patients demonstrated excellent correlation with 3D-TEE., Conclusions: This is the first study to demonstrate that the FEops HEARTguide model accurately predicts WATCHMAN FLX device implantation characteristics. Future studies are needed to evaluate if computational modeling can improve confidence in sizing, positioning, and compression of the device without compromising technical success., Competing Interests: Dr Vahl has received institutional funding to Columbia University Irving Medical Center from Boston Scientific, Edwards Lifesciences, JenaValve, Medtronic, and Siemens Healthineers; and has personally received consulting fees from Abbott Vascular, Boston Scientific, and Siemens Healthineers. Dr Sommer is a trainer for Boston Scientific’s Watchman device; is an investigator for the following Boston Scientific trials: OPTION and CHAMPION-AF; and is the National Principal Investigator on for two Gore trials: ASSURED and RELIEF. Dr Khalique is part of a corelab contracting with JenaValve, but has not received any direct compensation; has received consulting fees from Abbott Structural and Boston Scientific; and has received Speakers bureau fees from Edwards Lifesciences. Dr Hamid is part of a corelab contracting with JenaValve, but she has not received any direct compensation. Drs Bavo and De Beule are employees of FEops. Dr Hahn has received speaker fees from Abbot Vascular, Baylis Medical, Edwards Lifescience, and Philips Healthcare; institutional consulting contracts with no direct compensation for Abbott Structural, Edwards Lifesciences, Medtronic, Novartis, and Philips Healthcare; and equity with Navigate. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
133. Right Heart Morphology of Candidate Patients for Transcatheter Tricuspid Valve Interventions.
- Author
-
Khalique OK, Jelnin V, Hueske A, Lawlor M, Leon MB, Kodali SK, Akkoc D, Pettway E, Hahn RT, Hamid NB, George I, Patel A, Ng V, Vahl TP, Nazif TM, and Siefert AW
- Subjects
- Computed Tomography Angiography methods, Echocardiography, Hemodynamics, Humans, Tricuspid Valve diagnostic imaging, Tricuspid Valve surgery, Tricuspid Valve Insufficiency diagnostic imaging, Tricuspid Valve Insufficiency surgery
- Abstract
Purpose: This study quantitatively evaluated the phasic right heart morphology of candidate patients for a transcatheter tricuspid valve intervention (N=32) and of subjects with trace to no tricuspid regurgitation (N = 14)., Methods: Cardiac computed tomography angiography (CCTA) and transthoracic/transesophageal echocardiography (TTE/TEE) images were analyzed using dedicated research and clinical software. Using CCTA, the phasic right atrial and ventricular volumes, annulus dimensions, annulus-to-right coronary artery (RCA) distances, circumferential topography of the annular tissue shelf, vena cava dimensions (inferior and superior), vena cava positions, axis angles, and annular excursions were quantified. Using TTE/TEE, leaflet geometry, regurgitation, hemodynamics, and heart function were quantified. Measurements within and between groups were quantitatively compared with regression analyses to explore relationships between right heart features., Results: The phasic position and orientation of the vena cava and the circumferential topography of the annular tissue shelf were quantitatively presented for the first time. The candidate patient group exhibited greater chamber dimensions, enlarged vena cava, distended vena cava positions, positional shallowing of the annular tissue shelf, geometric annular distortion, leaflet distention, moderate or greater regurgitation, and impaired ventricular function. Atrial volume correlated strongly with directional vena cava positions as well as with annular dimensions. Annulus-to-RCA distances and annular excursions were comparable between groups., Conclusions: This study provides new and further insight to the right heart morphology and functional characteristics of candidate patients for a transcatheter tricuspid valve intervention. These data provide a platform from which these patients can continue to be better understood for further improving transcatheter system design and use., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
134. Debulking of a large right heart mass in a cancer patient using the Angiovac system.
- Author
-
Lebehn M, Kampaktsis PN, Sethi S, and Hamid N
- Published
- 2020
- Full Text
- View/download PDF
135. Killing two birds with one stone-MitraClip for flail P2 and systolic anterior motion of mitral valve: a case report.
- Author
-
Wong N, Hamid N, Tang HC, and Yeo KK
- Abstract
Background: The MitraClip system has been used extensively in high-risk patients with severe degenerative mitral regurgitation (MR). Recent reports have demonstrated the feasibility of using the MitraClip device to treat systolic anterior motion (SAM) of the mitral valve in obstructive hypertrophic cardiomyopathy (HOCM)., Case Summary: We report the case of a 76-year-old lady who had both symptomatic severe degenerative MR and HOCM that were refractory to medical therapy. Both pathologies were treated successfully using the MitraClip system., Discussion: In patients who are deemed to be at high risk for open surgery, our case demonstrated the feasibility of a percutaneous avenue, the MitraClip system, to treat not just degenerative MR, but also SAM from HOCM in a single procedure.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.